vs
NEOGENOMICS INC（NEO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
NEOGENOMICS INC的季度营收约是再鼎医药的1.5倍（$186.7M vs $127.1M），再鼎医药同比增速更快（17.1% vs 11.1%），过去两年再鼎医药的营收复合增速更高（20.8% vs 6.5%）
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
NEO vs ZLAB — 直观对比
营收规模更大
NEO
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出6.0%
11.1%
两年增速更快
ZLAB
近两年复合增速
6.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $186.7M | $127.1M |
| 净利润 | $-108.0M | — |
| 毛利率 | 43.3% | 51.0% |
| 营业利润率 | 46.9% | -54.6% |
| 净利率 | -57.9% | — |
| 营收同比 | 11.1% | 17.1% |
| 净利润同比 | 42.0% | — |
| 每股收益（稀释后） | $-0.13 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOZLAB
| Q1 26 | $186.7M | — | ||
| Q4 25 | $190.2M | $127.1M | ||
| Q3 25 | $187.8M | $115.4M | ||
| Q2 25 | $181.3M | $109.1M | ||
| Q1 25 | $168.0M | $105.7M | ||
| Q4 24 | $172.0M | $108.5M | ||
| Q3 24 | $167.8M | $101.8M | ||
| Q2 24 | $164.5M | $100.1M |
净利润NEOZLAB
| Q1 26 | $-108.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-27.1M | $-36.0M | ||
| Q2 25 | $-45.1M | $-40.7M | ||
| Q1 25 | $-25.9M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-17.7M | $-41.7M | ||
| Q2 24 | $-18.6M | $-80.3M |
毛利率NEOZLAB
| Q1 26 | 43.3% | — | ||
| Q4 25 | 43.8% | 51.0% | ||
| Q3 25 | 42.8% | 59.5% | ||
| Q2 25 | 42.6% | 60.6% | ||
| Q1 25 | 43.6% | 63.6% | ||
| Q4 24 | 44.9% | 61.5% | ||
| Q3 24 | 44.6% | 64.1% | ||
| Q2 24 | 44.1% | 64.9% |
营业利润率NEOZLAB
| Q1 26 | 46.9% | — | ||
| Q4 25 | -7.1% | -54.6% | ||
| Q3 25 | -14.4% | -42.3% | ||
| Q2 25 | -26.3% | -50.3% | ||
| Q1 25 | -16.6% | -53.3% | ||
| Q4 24 | -10.7% | -62.6% | ||
| Q3 24 | -12.6% | -66.6% | ||
| Q2 24 | -13.3% | -76.0% |
净利率NEOZLAB
| Q1 26 | -57.9% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -14.4% | -31.2% | ||
| Q2 25 | -24.9% | -37.3% | ||
| Q1 25 | -15.4% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -10.5% | -40.9% | ||
| Q2 24 | -11.3% | -80.2% |
每股收益（稀释后）NEOZLAB
| Q1 26 | $-0.13 | — | ||
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.1M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $828.8M | $715.5M |
| 总资产 | $1.3B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NEOZLAB
| Q1 26 | $146.1M | — | ||
| Q4 25 | $159.6M | $689.6M | ||
| Q3 25 | $164.1M | $717.2M | ||
| Q2 25 | $154.7M | $732.2M | ||
| Q1 25 | $346.2M | $757.3M | ||
| Q4 24 | $367.0M | $779.7M | ||
| Q3 24 | $362.0M | $616.1M | ||
| Q2 24 | $355.1M | $630.0M |
总债务NEOZLAB
| Q1 26 | — | — | ||
| Q4 25 | $341.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $541.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益NEOZLAB
| Q1 26 | $828.8M | — | ||
| Q4 25 | $836.6M | $715.5M | ||
| Q3 25 | $838.3M | $759.9M | ||
| Q2 25 | $854.0M | $791.7M | ||
| Q1 25 | $888.3M | $810.8M | ||
| Q4 24 | $902.3M | $840.9M | ||
| Q3 24 | $908.2M | $667.7M | ||
| Q2 24 | $915.9M | $704.2M |
总资产NEOZLAB
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.4B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.6B | $985.3M | ||
| Q2 24 | $1.6B | $987.4M |
负债/权益比NEOZLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.60× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流NEOZLAB
| Q1 26 | $-8.1M | — | ||
| Q4 25 | $1.3M | $-26.0M | ||
| Q3 25 | $8.9M | $-32.0M | ||
| Q2 25 | $20.3M | $-31.0M | ||
| Q1 25 | $-25.3M | $-61.7M | ||
| Q4 24 | $9.8M | $-55.8M | ||
| Q3 24 | $9.2M | $-26.8M | ||
| Q2 24 | $13.9M | $-42.2M |
自由现金流NEOZLAB
| Q1 26 | — | — | ||
| Q4 25 | $-6.5M | $-26.7M | ||
| Q3 25 | $570.0K | $-35.0M | ||
| Q2 25 | $14.0M | $-33.9M | ||
| Q1 25 | $-29.8M | $-63.2M | ||
| Q4 24 | $-1.8M | $-58.4M | ||
| Q3 24 | $-1.6M | $-28.2M | ||
| Q2 24 | $814.0K | $-42.9M |
自由现金流率NEOZLAB
| Q1 26 | — | — | ||
| Q4 25 | -3.4% | -21.0% | ||
| Q3 25 | 0.3% | -30.4% | ||
| Q2 25 | 7.7% | -31.1% | ||
| Q1 25 | -17.8% | -59.9% | ||
| Q4 24 | -1.0% | -53.8% | ||
| Q3 24 | -0.9% | -27.7% | ||
| Q2 24 | 0.5% | -42.9% |
资本支出强度NEOZLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 0.5% | ||
| Q3 25 | 4.4% | 2.6% | ||
| Q2 25 | 3.5% | 2.6% | ||
| Q1 25 | 2.7% | 1.5% | ||
| Q4 24 | 6.7% | 2.4% | ||
| Q3 24 | 6.4% | 1.3% | ||
| Q2 24 | 8.0% | 0.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEO
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
